Abstract 5383
Background
Cancer survivorship is increasing yet cancer treatment can cause de-conditioning and reduce physical capacity. Consequently there is a need to identify interventions which can improve health. This study investigated the impact of a personalised self-management programme on the physical and psychological health of cancer survivors with lifestyle related health risks.
Methods
For the purpose of this research the Moving on Programme was developed which is an intervention for cancer survivors to self-manage lifestyle. A randomised control pilot trial was conducted on 123 cancer survivors with a BMI > 25. Participants were randomly assigned to the control (n = 61) or intervention (n = 62) groups. The intervention group attended the Moving on Programme and engaged in personalised goal-setting to incrementally increase physical activity and made dietary changes. Participants in the control group received only brief standard advice. Objective measures of health behaviour were collected via Fitbit. Data on anthropometric, physiological, dietary behaviour and psychological measures were collected on all participants at baseline, three and six months. A sample of participants were interviewed (n = 13) to examine acceptability of the intervention.
Results
Overall, the results demonstrate a positive effect of the Moving on Programme. There was a significant reduction in BMI observed within the intervention group (p = 0.05) in the first three months. Positive participant outcomes also included improvement in physical and psychological wellbeing, and social functioning with reduced fatigue. Qualitative data demonstrated the acceptability of the intervention and participants identified that the Moving on Programme fulfils a deficit that exists in cancer survivorship and rehabilitation.
Conclusions
The Moving on Programme designed for this study, demonstrated physical and psychological benefits to participants. The use of behaviour change techniques and mobile technology was used effectively as an acceptable intervention that supports weight loss, promotes healthier behaviours and improves wellbeing in cancer survivors.
Clinical trial identification
ISRCTN18676721 https://doi.org/10.1186/ISRCTN18676721.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Irish Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4290 - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.
Presenter: Alessio Fiascarelli
Session: Poster Display session 3
Resources:
Abstract
2167 - Neat-1: culprit lnRNA tying PIG-C, MSLN, CD80 in TNBC
Presenter: Nada Hussein
Session: Poster Display session 3
Resources:
Abstract
1829 - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
Presenter: Hisako Ono
Session: Poster Display session 3
Resources:
Abstract
4357 - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Presenter: Eva Galan-Moya
Session: Poster Display session 3
Resources:
Abstract
5163 - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer
Presenter: Alex Eustace
Session: Poster Display session 3
Resources:
Abstract
832 - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Presenter: Jia-Hong Chen
Session: Poster Display session 3
Resources:
Abstract
3781 - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Presenter: Ana Lucia Sanabria
Session: Poster Display session 3
Resources:
Abstract
3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)
Presenter: Patrick Robelin
Session: Poster Display session 3
Resources:
Abstract
3391 - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Presenter: Pavlina Spiliopoulou
Session: Poster Display session 3
Resources:
Abstract
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract